VISN 5 MIRECC - General Publications 2008 - MIRECC / CoE
Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

MIRECC / CoE

Menu
Menu

Quick Links

Veterans Crisis Line Badge
My healthevet badge
 

VISN 5 MIRECC - General Publications 2008

 

About Us • Clinical • Education • Research
VISN 5 MIRECC home

 

Bellack, A.S. (2008). Psychosocial rehabilitation. In A. Tasman, J.A., Lieberman, M.B. First, & M. Maj (Eds), Psychiatry (Third ed). New York: John Wiley & Sons.

Buchanan, R. W., Conley, R. R., Dickinson, D., Ball, M. P., Feldman, S., Gold, J. M., & McMahon, R. P. (2008). Galantamine for the treatment of cognitive impairments in patients with schizophrenia. American Journal of Psychiatry, 165(1), 82-89.

Carpenter, W. T. (2008). More changes for the Schizophrenia Bulletin [editorial]. Schizophrenia Bulletin, 34(1), 1-2.

Carpenter, W. T., & Buchanan, R. W. (2008). Lessons to take home from CATIE. Psychiatric Services, 59(5), 523-525.

Carpenter, W. T., & Koenig, J. I. (2008). The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology, 33, 2061-2079.

Chinman, M., Lucksted, A., Gresen, R., Davis, M., Losonczy, M., Sussner, B., & Martone, L. (2008). Early experiences of consumer providers in the VA. Psychiatric Services, 59(11), 1315-1321.

Cohen, A. N., Glynn, S. M., Murray-Swank, A. B., Barrio, C., Fischer, E. P., McCutcheon, S. J., Perlick, D. A., Rotondi, A. J., Sayers, S. L., Sherman, M. D., & Dixon, L. B. (2008). The family forum: present and future directions in the implementation and dissemination of family psychoeducation. Psychiatric Services, 59, 40-48.

Cook, J., Blyler, C., Burke-Miller, J., McFarlane, W., Leff, H. S., Mueser, K., Gold, P., Goldberg, R., Shafer, M., Onken, S., Donegan, K., Carey, M. A., Razzano, L., Grey, D., Pickett-Schenk, S., & Kaufmann, C. (2008). Effectiveness of supported employment for individuals with schizophrenia: results of a multi-site, randomized trial. Clinical Schizophrenia and Related Psychoses, 2(1), 37-46.

Deutsch, S. I., Rosse, R. B., Connor, J. M., Burket, J. A., Murphy, M. E., & Fox, F. J. (2008). Current status of cannabis treatment of multiple sclerosis with an illustrative case presentation of a patient with multiple sclerosis, complex vocal tics, paroxysmal dystonia and marijuana dependence treated with dronabinol. CNS Spectrums, 13(5), 393-403.

Deutsch, S. I., Rosse, R. B., Long, K. D., Gaskins, B. L., Burket, J. A., & Mastropaolo, J. (2008). Sodium butyrate, an epigenetic interventional strategy, attenuates a stress-induced alteration of MK-801’s pharmacologic action. European Neuropsychopharmacology, 18, 565-568.

Deutsch, S. I., Rosse, R. B., Long, K. D., Gaskins, B. L., & Mastropaolo, J. (2008). Guanosine possesses specific modulatory effects on NMDA receptor-mediated neurotransmission in intact mice. European Neuropsychopharmacology, 18, 299-302.

Deutsch, S. I., Rosse, R. B., Mastropaolo, J., Long, K. D., & Gaskins, B. L. (2008). Epigenetic therapeutic strategies of neuropsychiatric disorders: ready for prime time? Clinical Neuropharmacology, 31(2), 104-119.

Deutsch, S. I., Schwartz, B. L., Schooler, N. R., Rosse, R. B., Mastropaolo, J., & Gaskins, B. (2008). First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy. Clinical Neuropharmacology, 31(1), 34-39.

Dickerson, F., Brown, C. H., Fang, L., Goldberg, R. W., Kreyenbuhl, J., Wohlheiter, K., & Dixon, L., (2008). Quality of life in individuals with serious mental illness and Type 2 Diabetes. Psychosomatics, 49(2), 109-114.

Dickinson, D. (2008). Digit symbol coding and general cognitive ability in schizophrenia: worth another look? British Journal of Psychiatry, 193(5), 354-356.

Dickinson, D., & Gold, J. M. (2008). Less unique variance than meets the eye: overlap among traditional neuropsychological dimensions in schizophrenia. Schizophrenia Bulletin, 34(3), 423-434.

Dickinson, D., Gold, J. M., Dickerson, F. B., Medoff, D., & Dixon, L. B. (2008). Evidence of exacerbated cognitive deficits in schizophrenia patients with co-morbid diabetes. Psychosomatics, 49(2), 123-131.

Dickinson, D., & Harvey, P. D. (2008). Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Schizophrenia Bulletin. Aug 9, 2008. [Epub ahead of print]

Dickinson, D., Ragland, J. D., Gold, J. M., & Gur, R. C. (2008). General and specific cognitive deficits in schizophrenia: Goliath defeats David? Biological Psychiatry. May 8. [Epub ahead of print].

DiClemente, C. C., Nidecker, M., & Bellack, A.S. (2008). Motivation and the stages of change among individuals with co-occurring disorders. Journal of Substance Abuse Treatment, 34, 25-35.

Drapalski, A., Milford, J., Goldberg, R., Brown, C. W., & Dixon, L. (2008). Perceived barriers to medical and mental health care among veterans with serious mental illness. Psychiatric Services, 59, 921-924

Drapalski, A. L., Marshall, T., Seybolt, D., Medoff, D., Peer, J., Leith, J., & Dixon, L. B. (2008). The unmet needs of families of individuals with mental illness and preferences regarding family services. Psychiatric Services, 59(6), 655-662.

Glynn, S., Dixon, L., Cohen, A., & Murray-Swank, A. (2008). The family member provider outreach program: an innovative way to engage family members in mental health care. Psychiatric Services, 59, 934.

Gold, J. M., Waltz, J. A., Prentice, K. J., Morris, S. E., & Heerey, E. A. (2008). Reward processing in schizophrenia: a deficit in the representation of value. Schizophrenia Bulletin, 34, 835-847.

Goldberg, R, Hackman, A., Medoff, D., Brown, C., Dickerson, F., Fang, L., Kreyenbuhl, J., & Dixon, L. (2008). Physical wellness and employment status and adults with serious mental illness. Community Mental Health Journal, 44(4), 245-251.

Goldberg, R., & Seth, P. (2008). Hepatitis C services and individuals with serious mental illness. Community Mental Health Journal, 44(5), 381-84.

Green, M. F, Penn, D. L., Bentall, R., Carpenter, W. T., Gaebel, W., Gur, R. C., Kring, A. M., Park, S., Silverstein, S. M., & Heinssen, R. (2008). Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophrenia Bulletin. Advance Access published on January 8, 2008. doi:10.1093/schbul/sbm145

Hong, L. E., Turano, K. A., O’Neill, H., Hao, L., Wonodi, I., Elliott, A., & Thaker, G. K. (2008). Refining the predictive pursuit endophenotype in schizophrenia. Biological Psychiatry, 63(5), 458-464.

Hong, L. E., Wonodi, I. O., Stine, C., Mitchell, B. D., & Thaker, G. K. (2008). Evidence of missense mutations on the neuregulin 1 gene affecting function of prepulse inhibition. Biological Psychiatry, 63(1), 17-23.

Kelly, D. L., McMahon, R. P., Weiner, E., Boggs, D. L., Dickinson, D., Conley, R. R., & Buchanan, R. W. (2008). Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia. Schizophrenia Research, 103, 161-168.

Kemp, A. S., Schooler, N. R., Kalali, A. H., Alphs, L., Anand, R., Awad, G., Davidson, M., Dube, S., Ereshefsky, L., Gharabawi, G., Leon, A. C., Lepine, J. P., Potkin, S., & Vermeulen, A. (2008). What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophrenia Bulletin. August 22. [Epub ahead of print].

Kreyenbuhl, J., Dixon, L. B., McCarthy, J. F., Soliman, S., Ignacio, R. V., & Valenstein, M. (2008). Does adherence to medications for Type 2 diabetes differ between individuals with versus without schizophrenia? Schizophrenia Bulletin. Aug 20, 2008. [E-pub ahead of print]

Kreyenbuhl, J., Medoff, D. R., Seliger, S. L., & Dixon, L. B. (2008). Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes. Schizophrenia Research, 101, 256-265.

Lucksted, A., Stewart, B., Dixon, L. B., & Forbes, C. (2008). Benefits and changes for family to family graduates. American Journal of Community Psychology, 42, 154-166.

McMahon, R. P., Kelly, D. L., Boggs, D. L., Li, L., Hu, Q., Davis, J. M., & Carpenter, W. T. (2008). Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research. Schizophrenia Bulletin, 34(2), 292-301.

Morris, S. E., Heerey, E. A., Gold, J. M., & Holroyd, C. B. (2008). Learning-related changes in brain activity following errors and performance feedback in schizophrenia. Schizophrenia Research, 99(1-3), 274-285.

Nidecker, M. F., DiClemente, C. C., Bennett, M. E., & Bellack, A. S. (2008). Application of the Transtheoretical Model of Change: Psychometric properties of leading measures in patients with co-occurring drug abuse and severe mental illness. Addictive Behaviors, 33, 1021-1030.

Peer, J., Strachan, E., & Spaulding, W. (2008). Heterogeneity in behavioral treatment response in severe mental illness. Journal of Nervous and Mental Disease, 196, 198-206.

Perera, P. Y., Lichy, J. H., Mastropaolo, J., Rosse, R. B., & Deutsch, S. I. (2008). Expression of NR1, NR2A, and NR2B NMDA receptor subunits is not altered in the genetically-inbred Balb/c mouse strain with heightened behavioral sensitivity to MK-801, a noncompetitive NMDA receptor antagonist. European Neuropsychopharmacology, 18(11), 814-819.

Salkever, D. S., Johnston, S., Karakus, M., Ialongo, N., Slade, E. P., & Stuart, E. A. (2008). Enhancing the net benefits of disseminating new prevention programs: a note on target efficiency with illustrative examples. Administration and Policy in Mental Health and Mental Health Services Research. March 15. [Epub ahead of print].

Silverstein, S. M., & Bellack, A. S. (2008). A Scientific Agenda for the Concept of Recovery as it Applies to Schizophrenia. Clinical Psychology Review, 28, 1108-1124.

Slade, E. P., Stuart, E. A., Salkever, D. S., Karakus, M., Green, K., & Ialongo, N. (2008). Impacts of age on onset of substance use disorders on risk of adult incarceration among disadvantaged urban youth: a propensity score matching approach. Drug and Alcohol Dependence, 95(1-2), 1-13.

Smelson, D. A., Dixon, L., Craig, T., Remolina, S., Batki, S., Niv, N., & Owen, R. (2008). Pharmacological treatment of schizophrenia and co-occurring substance use disorders. CNS Drugs, 22(11), 903-916.

Tenhula, W. N., & Bellack, A. S. (2008). Social skills training. In K. T. Mueser & D. V. Jeste (Eds), Clinical handbook of schizophrenia. New York: Guilford Press.

Tenhula, W. N., Bellack, A. S., & Drake, R. E. (2008). Schizophrenia: psychosocial approaches. In B. J. Sadock & V. A. Saddock (Eds.), Kaplan & Sadock’s Comprehensive textbook of psychiatry (3rd Edition). Baltimore: Lippincott, Williams, & Wilkins.

Thaker, G. (2008). Psychosis endophenotypes in schizophrenia and bipolar disorder. Schizophrenia Bulletin, 34(4), 720-721.

Thaker, G. K. (2008). Neurophysiological endophenotypes across bipolar and schizophrenia psychosis. Schizophrenia Bulletin, 34(4), 760-773.

Wonodi, I., Hong, L. E., & Thaker, G. K. (2008). Molecular Pathology. In G. K. Thaker & W. T. Carpenter, The Year in Schizophrenia (Vol. 2). Portland: Book News, Inc.

Zhu, B., Ascher-Svanum, H., Faries, D. E., Peng, X., Salkever, D., & Slade, E. P. (2008). Costs of treating patients with schizophrenia who have illness-related crisis events. BMC Psychiatry, 8(72). DOI:10.1186/1471-244X-8-72 2008.

 

NOTE: Names in bold are VISN 5 MIRECC Investigators